Suchergebnisse - "Asselah, Tarik"

PubPharm (37)

1

Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1) : a multicentre, double-blind, active-controlled, randomised, phase 2b trial

enthalten in: The lancet. Gastroenterology & hepatology | 2023

von Yuen, M. | Asselah, T. | Jacobson, I. | +116

CommentIn: Lancet Gastroenterol Hepatol. 2023 Sep;8(9):772-773. - PMID 37442151

2

Evolution of Hepatitis C Virus Treatment During the Era of Sofosbuvir-Based Therapies : A Real-World Experience in France

enthalten in: Digestive diseases and sciences | 2021

von Ouzan, D. | Larrey, D. | Guyader, D. | +49

3

Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2020

von Abergel, A. | Asselah, T. | Mallat, A. | +19

4

Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection : A randomized study

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2020

von Asselah, T. | Pol, S. | Hezode, C. | +21

5

Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B

enthalten in: PloS one | 2020

von Marcellin, P. | Xie, Q. | Woon Paik, S. | +14

6

Obeticholic acid for the treatment of non-alcoholic steatohepatitis : interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

enthalten in: Lancet (London, England) | 2019

von Younossi, Z. | Ratziu, V. | Loomba, R. | +133

CommentIn: Lancet. 2019 Dec 14;394(10215):2131-2133. - PMID 31813639

7

Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment : a prospective cohort study

enthalten in: Lancet (London, England) | 2019

von Carrat, F. | Fontaine, H. | Dorival, C. | +37

CommentIn: Lancet. 2019 Apr 6;393(10179):1392-1394. - PMID 30765125

8

Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6) : an open-label, multicentre, phase 3b trial

enthalten in: The lancet. Gastroenterology & hepatology | 2019

von Asselah, T. | Lee, S. | Yao, B. | +13

CommentIn: Lancet Gastroenterol Hepatol. 2019 Jan;4(1):5-6. - PMID 30527582

9

Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older

enthalten in: PloS one | 2019

von Foster, G. | Asselah, T. | Kopecky-Bromberg, S. | +5

10

Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection : A pooled analysis

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2018

von Asselah, T. | Reesink, H. | Gerstoft, J. | +10